Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) EBT Margin (2016 - 2025)

Lineage Cell Therapeutics' EBT Margin history spans 16 years, with the latest figure at 93.14% for Q4 2025.

  • For Q4 2025, EBT Margin rose 2017.0% year-over-year to 93.14%; the TTM value through Dec 2025 reached 239.96%, down 4434.0%, while the annual FY2025 figure was 471.61%, 27599.0% down from the prior year.
  • EBT Margin reached 93.14% in Q4 2025 per LCTX's latest filing, roughly flat from 92.91% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 56.02% in Q4 2021 to a low of 969.73% in Q2 2021.
  • Average EBT Margin over 5 years is 307.66%, with a median of 242.95% recorded in 2023.
  • Peak YoY movement for EBT Margin: surged 126936bps in 2021, then plummeted -38852bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 56.02% in 2021, then plummeted by -493bps to 332.22% in 2022, then surged by 32bps to 225.77% in 2023, then skyrocketed by 50bps to 113.32% in 2024, then rose by 18bps to 93.14% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's EBT Margin are 93.14% (Q4 2025), 92.91% (Q3 2025), and 698.95% (Q2 2025).